Asthma inflammatory phenotypes on four continents: most asthma cases are non-eosinophilic ========================================================================================= * Lucy Pembrey * Collin Brooks * Harriet Mpairwe * Camila A Figueiredo * Aida Y. Oviedo * Martha Chico * Irene Nambuya * Pius Tumwesige * Steven Robertson * Susan Ring * Mauricio L. Barreto * Philip J. Cooper * John Henderson * Alvaro A. Cruz * Jeroen Douwes * Neil Pearce * the WASP Study Group ## Abstract The World Asthma Phenotypes (WASP) study is being conducted in five centres in Brazil, Ecuador, Uganda, New Zealand and the United Kingdom, with a range of prevalence levels and exposures, and a likely range of phenotype distributions. Here we present the main findings with regards to asthma inflammatory phenotypes. We recruited 998 cases and 356 controls: 204/40 in Brazil, 176/67 in Ecuador, 207/50 in Uganda, 235/132 in New Zealand, and 176/67 in the United Kingdom. All centres studied children and adolescents (age-range 8–20 years), with the exception of the UK centre which involved 26–27 year olds. The proportion of participants who produced sputum samples was 87%, with a range from 74% (Brazil) to 91% (Ecuador), and of these 62% were countable with regards to the inflammatory cell types.The proportions of asthma cases who were classified as eosinophilic or mixed granulocytic asthma (the two inflammatory phenotypes which involve eosinophilia) was 39% overall: 35% in Brazil, 32% in Ecuador, 33% in Uganda, 50% in New Zealand, and 28% in the United Kingdom. The non-eosinophilic asthmatics (NEA) had similar chronic severity (e.g. in terms of attacks in the previous year) to the eosinophilic asthmatics (EA). Of the 61% of cases with NEA, 50% showed no signs of inflammation (paucigranulocytic), with 11% having neutrophilic inflammation. This is the first time that sputum induction has been used in a standardised manner to compare asthma inflammatory phenotypes in high income countries (HICs) and low-and-middle-income countries (LMICs). It confirms that most cases are non-eosinophilic, with the proportions ranging from 50% to 72%, across these varied environments; most of these non-eosinophilic cases were paucigranulocytic, with no sign of airways inflammation. ## Introduction It is now well established in high-income countries (HICs) that there are multiple phenotypes and endotypes of asthma1, 2, and that less than one half of asthma cases are attributable to eosinophilic airways inflammation3, 4. Most asthma in low- and middle-income countries (LMICs) appears to be non-atopic5, the association between atopy and asthma is much weaker than in high income countries (HICs)5, 6, and standardised comparisons across populations or time periods also show only weak and inconsistent associations between the prevalence of atopy and the prevalence of asthma5. However, there have been few standardized comparisons of asthma phenotypes between HICs and LMICs. Asthma phenotypes can be defined in a number of different ways, and can include clinical, demographic and pathological characteristics of asthma7. Similarly, atopy can be defined and measured in a variety of ways, including skin-prick tests, serum IgE, and eosinophilic inflammation of the airways. Our focus in the current paper is on inflammatory phenotypes, defined in terms of airways inflammation. A recent Lancet Commission report on asthma called for greater recognition of the various phenotypes with different underlying pathological mechanisms, often grouped under the non specific label of asthma. The importance of non-eosinophilic asthma in particular was highlighted at a recent Academia Europea/Asthma UK meeting8. The meeting report notes that asthma was originally thought to be a disease of airways smooth muscle, but subsequent guidelines highlighted the role of eosinophilic airways inflammation and anti-inflammatory therapies (inhaled corticosteroids (ICS)), and non-eosinophilic asthma “responds only poorly to the long-standing, conventional treatments traditionally used to reduce inflammation of the airways such as ICS”8. Characterisation of asthma inflammatory phenotypes is therefore important to: (i) better understand the aetiological mechanisms of asthma; (ii) identify specific causes; (iii) guide the development of new therapeutic measures that are effective for all asthmatics; and (iv) enable better management and prevention of asthma in both HICs and LMICs. For these reasons we have formed the World ASthma Phenotypes (WASP) international collaboration to investigate and characterise asthma phenotypes in more depth in HICs and LMICs. The study is initially being conducted in five countries, and the detailed rationale and protocol have been published elsewhere7. WASP is studying a number of different aspects of asthma phenotypes, but in this first paper, we present the main study findings with regards to asthma inflammatory phenotypes. ## Methods The detailed study methods have been published elsewhere7, but are briefly summarized here. The study was conducted in five centres; Bristol in the UK (Avon Longitudinal Study of Parents and Children, ALSPAC), Wellington in New Zealand, Salvador in Brazil, Quininde in Ecuador and Entebbe in Uganda (Table 1) with a range of prevalence levels and exposures, and a likely range of phenotype distributions. View this table: [Table 1:](http://medrxiv.org/content/early/2020/08/25/2020.08.23.20177162/T1) Table 1: Collaborating studies and centres, and characteristics of study participants In each centre, the aim was to recruit a minimum of 200 asthma cases and 50 non-asthmatics. The focus was on defining categories within the groups of asthmatics; however, in each centre, a comparison was also made with non-asthmatics in order to check that the derived asthma inflammatory phenotypes do in fact distinguish asthmatics from non-asthmatics. ### Asthmatics Cases were identified as those with symptoms of asthma and/or use of asthma medication in the past 12 months, using the International Study of Asthma and Allergies in Childhood (ISAAC) or (in adults) the European Community Respiratory Health Survey (ECRHS) questionnaires (the same key questions occur in both questionnaires). ### Non-asthmatics Non-asthmatics were identified as having no previous or current history of asthma, using the ISAAC and ECRHS questionnaires. #### Data collection Information was collected using standardised methods and operational procedures. These included risk factor questionnaires, clinical characterisation, and blood, and induced sputum samples. We repeated the sputum samples after approximately three months in a sub-group of asthmatics. ### Questionnaire As well as questions on current living conditions and other risk/protective factors (not reported here), we also included questions on the frequency and severity of clinical symptoms, and on use of asthma medications. These were based on the International Study of Asthma and Allergies in Childhood (ISAAC) Phase II (asthma management) and Phase III (environmental risk factors) modules, and additional questions on asthma control were added (Asthma Control Questionnaire, E Juniper, UK/English version Sept 2010, Mapi Research Institute9). We used the standard ISAAC definition of chronic severe asthma as those with current wheeze who have more than 4 attacks of wheezing in the last 12 months, or more than one night per week sleep disturbance, or wheeze affecting speech10. ### Skin prick tests Skin prick tests (SPT) were carried out according to a well-defined protocol11, 12. Histamine and saline were used as positive and negative controls, respectively. Fifteen minutes after testing, a mean wheal size of 3mm or greater was considered positive, once reaction to the negative control has been subtracted. SPT positivity was defined as a positive SPT to at least one of a panel of at least eight commercially available allergens, including house dust mite (*Dermatophagoides pteronyssinus*), tree pollen mix, grass pollen mix, cat and dog dander, *Alternaria tenuis*, Penicillium mix, plus locally relevant allergens. ### Lung function testing Lung function testing was conducted according to American Thoracic Society (ATS) criteria. All spirometers were regularly tested and calibration checks was conducted weekly by research staff when in use. Lung function testing was carried out with participants in a sitting position. Three reproducible forced expiratory manoeuvres was performed. ### Sputum induction Sputum induction was conducted using a standardised protocol involving saline inhalation that we have used previously13, adapted from the protocol developed by Peter Gibson et al14. Participants were pre-treated with 200mg salbutamol, and 4.5% hypertonic saline administered by oral inhalation using an ultrasonic nebuliser for increasing intervals from 30 seconds to 4 minutes, to a total of 15.5 minutes; at the end, participants will produce a sputum sample in a sterile plastic container. Induced sputum was processed within two hours of collection. Where possible, at least 100µl of sputum plugs was selected from the sample, and the volume measured. Dithiothreitol is then added to the selected pellet and the mixture dispersed before being filtered through a 60µm nylon mesh. The resulting suspension is centrifuged and the supernatant removed and stored at –80°C for subsequent laboratory analyses. The pellet is re-suspended and cell viability (trypan blue exclusion) and total cell count determined using a haemocytometer. A differential cell count of 400 non-squamous sputum cells was conducted using light microscopy.The sputum slides were all read in Wellington, New Zealand, with the exception of the Brazil slides which could not be shipped overseas because of restrictions on samples containing DNA: these were therefore read in Brazil, with a sample of slides being checked (via the internet) by the group in Wellington. ## Results Table 1 summarizes the characteristics of the study centres and participants. Overall, we recruited 998 asthma cases and 356 controls. All centres included children and adolescents (age-range 8–20 years), except for the UK centre for which the participants were 26–27 years. View this table: [Table 2:](http://medrxiv.org/content/early/2020/08/25/2020.08.23.20177162/T2) Table 2: Clinical characteristics by centre Table 2 summarizes the clinical characteristics of the participants by centre. The participants were chosen to be a representative sample of asthmatics in general, rather than focussing on severe asthma, and this is reflected in the clinical indicators. Nevertheless, using the ISAAC definition10 (which is based on symptoms in the previous year), the proportion of participants with severe asthma ranged from 45% (UK, Ecuador) to 66% (Brazil, Uganda). The proportion of cases who were skin-prick-test (SPT) positive ranged from 35% (Ecuador) to 84% (Brazil). The proportion of controls who were SPT+ ranged from 13% (Uganda) to 65% (Brazil). Table 3 summarizes the sputum slide results by centre. The proportion of participants who produced a sputum sample ranged from 74% (Brazil) to 93% (UK). Of these, the proportion of countable sputum slides ranged from 40% (UK) to 95% (New Zealand). The proportions with eosinophilic asthma (EA), i.e. either eosinophilic or mixed granulocytic inflammatory cell types, varied greatly across the five centres. For the four centres which involved children and adolescents, the proportion with EA was one-half (50%) in New Zealand, compared with about one-third (32%-35%) in the LMIC centres; in contrast, the only centre which involved adults (Bristol) was in a HIC but had the lowest prevalence (28%) of EA. Regarding the inflammatory subtypes, the findings were reasonably consistent across centres, with a predominance of eosinophilic and paucigranulocytic asthma, neither of which involve high levels of neutrophils. The exception was Uganda, where a high proportion of non eosinophilic cases had high levels of neutrophils. However, this proportion was higher in the controls (60%) than in the cases (35%). We also examined the repeatability of the phenotyping with a repeat sputum induction test done 3–6 months after the original test. Between 57% and 75% of participants had the same general phenotype (EA or NEA) across the two tests, with roughly equal numbers switching from EA to NEA and vice versa. View this table: [Table 3:](http://medrxiv.org/content/early/2020/08/25/2020.08.23.20177162/T3) Table 3: Sputum slide results by centre The characteristics of the four inflammatory phenotypes in each centre are given in Appendix 1. Overall, there was little difference in chronic severity in the last 12 months, using the ISAAC definition10, across the four inflammatory phenotypes: the proportions with severe asthma were 59% for eosinophilic, 68% for mixed granulocytic, 43% for neutrophilic, and 45% for paucigranulocytic. These proportions are relatively high, given that most participants had well-controlled asthma, but this reflects the ISAAC definition which is based on symptoms in the last year and yields higher estimates of chronic asthma severity than do other definitions which focus on acute clinical severity. Appendix 2 shows the sputum results excluding low quality slides (those with less than 400 total non-squamous cells, and > 30% squamous cells). The findings changed little; for example, the proportions with eosinophilic or mixed granulocytic asthma changed from 28% to 31% in the UK, 50% to 52% in New Zealand, 35% to 32% in Brazil, 32% to 33% in Ecuador, and 33% to 29% in Uganda. ## Discussion This is the first time that sputum induction has been used in a standardised manner to compare asthma inflammatory phenotypes in centres in high income countries (HICs) and low-and-middle-income countries (LMICs). There are several key findings that should be considered. Firstly, for the four centres which involved children and adolescents, this study confirms previous research in HICs that only about one-half, or less, of current asthmatics have EA, and it shows for the first time that only about one-third of asthmatics in the centres in LMICs have EA. The proportions of asthma cases who were classified as eosinophilic or mixed granulocytic asthma (the two inflammatory phenotypes which involve eosinophilia, based on >2.5% of cells being eosinophils) was 35% in Brazil, 32% in Ecuador, 33% in Uganda, and 50% in New Zealand. However, the centre in the United Kingdom (also a high income country) yielded the lowest estimate – 28% in 26–27 year olds. It is possible that this difference between the United Kingdom and New Zealand is due to the different age-groups that were studied. However, it is reasonably consistent with the findings of the ISAAC Phase II study5 which was conducted in 8–12 year-olds: the proportions with positive skin prick tests were 35.6% in New Zealand compared with 17.5% in the UK; the proportion of asthma cases (wheeze in the last year) that were skin-prick-test positive were 60% and 39% respectively. Thus, it is possible that this finding represents a real difference between the United Kingdom and New Zealand which warrants further investigation, given that both are high-income countries with similar levels of asthma prevalence15. Secondly, there was a high proportion of neutrophilic cases in Uganda. However, this was actually lower in the asthma cases (35%) than in the controls (50%). Thus it is possible that this reflects non-asthmatic neutrophilic inflammation due to environmental exposures (e.g. indoor air pollution, increased risk of infections, exposure to animals), but we do not have information to assess this hypothesis. It is notable, however, that all centres (with the exception of Ecuador, with small numbers) actually showed a higher proportion of neutrophilia in the controls (14% overall) than in the cases (11%). It is likely therefore that most, if not all, of the neutrophilic cases have neutrophilia incidentally and it is not integral to their asthma. Thirdly, the most striking finding is the high proportion of cases with neither eosinophilia or neutrophilia (i.e. paucigranulocytic asthma). This confirms findings from previous studies in HICs13, which have shown that a high proportion of asthmatics appear to have no airways inflammation, thus raising the possibility that non-inflammatory mechanisms (e.g. neural mechanisms16) may be involved in their asthma. Two objections may be raised against this hypothesis. One is that the inflammatory phenotype is unstable, and that children with inherently eosinophilic asthma may only show eosinophilic inflammation from time to time, particularly when they are having attacks. However, previous studies have shown the non-inflammatory phenotype to be relatively stable17–19, and we have found similar findings here: 68% had the same phenotype (EA or NEA) in the repeat sputum assessments. A second objection might be that those with paucigranulocytic asthma may not really have asthma, or may have extremely mild asthma. However, we found only small differences in chronic asthma severity between eosinophilic (59%), mixed granulocytic (68%), neutrophilic (43%) and paucigranulocytic (45%) asthma. Although the definition of chronic severity that we used (based on the ISAAC definition) produces relatively high severity estimates, we used a consistent definition across centres and inflammatory phenotypes, so it is noteworthy that we did not see major differences in severity between the phenotypes. Some of the limitations of this study should also be acknowledged. We endeavoured to obtain random population samples of asthmatics in each centre, by taking random samples in school, and by utilizing existing cohort studies. Standardizing the data collection (particularly the sputum induction) was difficult, and not all centres could obtain readable sputum samples from a high proportion of participants. There were also difficulties in reading some of the slides (particularly those with high proportions of squamous cells). However, the findings did not change when we restricted our analyses to high quality slides (Appendix 2). In summary, this is the first time that sputum induction has been used in a standardised manner to compare asthma inflammatory phenotypes in high income countries (HICs) and low-and-middle-income countries (LMICs). It confirms that most cases are non-eosinophilic, with the proportions ranging from 50% to 72%, across these varied environments; most of these non-eosinophilic cases were paucigranulocytic, with no sign of airways inflammation. ## Data Availability Data is currently not available. We will consider requests for data sharing after the main findings have been published. ## Acknowledgements The World ASthma Phenotypes (WASP) collaboration is based on the AsthmaPhenotypes study which is funded by the European Research Council under the European Union’s Seventh Framework Programme (FP7/2007–2013) / ERC grant agreement no 668954. ALSPAC: We are extremely grateful to all the families who took part in this study, the midwives for their help in recruiting them, and the whole ALSPAC team, which includes interviewers, computer and laboratory technicians, clerical workers, research scientists, volunteers, managers, receptionists and nurses. The UK Medical Research Council and Wellcome (Grant ref: 102215/2/13/2) and the University of Bristol provide core support for ALSPAC. Alison Elliott and Philip Cooper were funded by Wellcome Trust grant numbers 095778 and 088862, respectively. We would like to thank the participants of this study in all five WASP centres. ## Appendix 1: centre-specific participant and clinical characteristics by inflammatory phenotype ### Bristol View this table: [Table4](http://medrxiv.org/content/early/2020/08/25/2020.08.23.20177162/T4) ### New Zealand View this table: [Table5](http://medrxiv.org/content/early/2020/08/25/2020.08.23.20177162/T5) ### Brazil View this table: [Table6](http://medrxiv.org/content/early/2020/08/25/2020.08.23.20177162/T6) ### Ecuador View this table: [Table7](http://medrxiv.org/content/early/2020/08/25/2020.08.23.20177162/T7) ### Uganda View this table: [Table8](http://medrxiv.org/content/early/2020/08/25/2020.08.23.20177162/T8) ## Appendix 2: Comparison of sputum slide results, excluding low quality slides (<400 total non-squamous cells and ≥30% squamous cells) View this table: [Table9](http://medrxiv.org/content/early/2020/08/25/2020.08.23.20177162/T9) * Received August 23, 2020. * Revision received August 23, 2020. * Accepted August 25, 2020. * © 2020, Posted by Cold Spring Harbor Laboratory This pre-print is available under a Creative Commons License (Attribution-NonCommercial-NoDerivs 4.0 International), CC BY-NC-ND 4.0, as described at [http://creativecommons.org/licenses/by-nc-nd/4.0/](http://creativecommons.org/licenses/by-nc-nd/4.0/) ## References 1. 1.Edwards, M.R., et al., Addressing unmet needs in understanding asthma mechanisms: From the European Asthma Research and Innovation Partnership (EARIP) Work Package (WP)2 collaborators. Eur Respir J, 2017. 49(5). 2. 2.Pavord, I.D., et al., After asthma: redefining airways diseases. Lancet, 2017. 3. 3.Douwes, J., et al., Non-eosinophilic asthma: importance and possible mechanisms.[comment]. Thorax., 2002. 57(7): p. 643–8. 4. 4.Pearce, N., J. Pekkanen, and R. Beasley, How much asthma is really attributable to atopy? Thorax., 1999. 54(3): p. 268–72. 5. 5.Weinmayr, G., et al., Atopic sensitization and the international variation of asthma symptom prevalence in children. American Journal of Respiratory and Critical Care Medicine, 2007. 176(6): p. 565–574. 6. 6.Barreto, M.L., et al., Poverty, dirt, infections and non-atopic wheezing in children from a Brazilian urban center. Respiratory Research, 2010. 11. 7. 7.Pembrey, L., et al., Understanding asthma phenotypes: the World Asthma Phenotypes (WASP) international collaboration. ERJ Open Research, 2018. 4: p. 00013–2018. 8. 8.Asthma still kills: Urgent priorities for the international research community to treat, prevent and cure asthma. 2019, Asthma UK: London. 9. 9.Juniper, E.F., et al., Asthma Control Questionnaire in children: validation, measurement properties, interpretation. Eur Respir J, 2010. 36(6): p. 1410–6. 10. 10.Lai, C.K., et al., Global variation in the prevalence and severity of asthma symptoms: phase three of the International Study of Asthma and Allergies in Childhood (ISAAC). Thorax, 2009. 64(6): p. 476–83. 11. 11.Wickens, K., et al., Farm residence and exposures and the risk of allergic diseases in New Zealand children. Allergy, 2002. 57(12): p. 1171–9. 12. 12.Weiland, S.K., et al., Phase II of the international study of asthma and allergies in childhood (ISAAC II): rationale and methods. European Respiratory Journal, 2004. 24(3): p. 406–412. 13. 13.Brooks, C.R., et al., Absence of airway inflammation in a large proportion of adolescents with asthma. Respirology, 2016. 21(3): p. 460–466. 14. 14.Gibson, P.G., et al., Epidemiological association of airway inflammation with asthma symptoms and airway hyperresponsiveness in childhood. Am J Respir Crit Care Med, 1998. 158(1): p. 36–41. 15. 15.Asher, M.I., et al., Worldwide variations in the prevalence of asthma symptoms: International Study of Asthma and Allergies in Childhood (ISAAC). European Respiratory Journal, 1998. 12: p. 315–335. 16. 16.Baroffio, M., et al., Noninflammatory mechanisms of airway hyper-responsiveness in bronchial asthma: an overview. Ther Adv Respir Dis, 2009. 3(4): p. 163–74. 17. 17.Simpson, J.L., P. McElduff, and P.G. Gibson, Assessment and reproducibility of non-eosinophilic asthma using induced sputum. Respiration, 2010. 79(2): p. 147–51. 18. 18.Simpson, J.L., et al., Inflammatory subtypes in asthma: Assessment and identification using induced sputum. Respirology, 2006. 11(1): p. 54–61. 19. 19.van Veen, I.H., et al., Consistency of sputum eosinophilia in difficult-to-treat asthma: a 5-year follow-up study. J Allergy Clin Immunol, 2009. 124(3): p. 615–7, 617.e1–2.